Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with an unmet medical need, today announces that its management team will present the Company’s 2022 financial results on Thursday, March 30, 2023, during of a webcast presentation.
Inventiva’s 2022 financial results will be published on Wednesday March 29, 2023 at 4:00 p.m. (New York), 10:00 p.m. (Paris).